Skip to main content

2nd version European Guidance

Please find an updated version of the European guidance was published on EudraLex-10.

Go to document

The aim is to provide sponsors and investigators with guidance on how to mitigate the effects of the pandemic in order to protect the safety, well-being and integrity of trial participants and the integrity of the trial.

The new version contains additional or new information about:

  • Informed consent in trials with COVID-19 patients;
  • IMP transfer and stocks with patients or at sites;
  • Communication with authorities of temporary trial halts due to reasons which are unrelated to the safety of the trial participants;
  • Stocks of in critical vitro diagnostics and other medical devices used in a particular trial;
  • Safety reporting
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.